NASDAQ:EDAP - Edap Tms Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.50
  • Forecasted Upside: 55.20 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$7.41
▲ +0.09 (1.23%)
1 month | 3 months | 12 months
Get New Edap Tms Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EDAP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EDAP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$11.50
▲ +55.20% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Edap Tms in the last 3 months. The average price target is $11.50, with a high forecast of $13.00 and a low forecast of $10.00. The average price target represents a 55.20% upside from the last price of $7.41.
Buy
The current consensus among 3 investment analysts is to buy stock in Edap Tms. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/13/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/12/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/5/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/25/2021Lake Street CapitalInitiated CoverageBuyHigh
i
1/22/2021B. RileyBoost Price TargetBuy$11.50 ➝ $13.00Low
i
1/21/2021HC WainwrightBoost Price TargetBuy$6.00 ➝ $10.00High
i
1/12/2021B. RileyBoost Price TargetBuy$5.50 ➝ $11.50High
i
11/20/2020HC WainwrightBoost Price TargetBuy$5.00 ➝ $6.00Low
i
4/15/2020B. RileyInitiated CoverageBuy$5.50Medium
i
Rating by A. D'silva at B. Riley
4/1/2020HC WainwrightLower Price TargetBuy$6.50 ➝ $5.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/15/2019HC WainwrightReiterated RatingBuy$6.50High
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/30/2019HC WainwrightSet Price TargetBuy$7.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
6/11/2019HC WainwrightSet Price TargetBuy$7.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/17/2019HC WainwrightSet Price TargetBuy$7.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/3/2019HC WainwrightReiterated RatingBuy$6.50Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/16/2018HC WainwrightReiterated RatingBuy$7.00High
i
Rating by S. Ramakanth at HC Wainwright
9/4/2018HC WainwrightReiterated RatingBuyLow
i
Rating by S. Ramakanth at HC Wainwright
7/2/2018HC WainwrightReiterated RatingBuy$6.50Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/16/2018HC WainwrightReiterated RatingBuy$6.50Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/29/2018HC WainwrightSet Price TargetBuy$7.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/22/2017HC WainwrightReiterated RatingBuy$6.50N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
10/9/2017HC WainwrightReiterated RatingBuy$6.50N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/25/2017HC WainwrightReiterated RatingBuy$6.50High
i
Rating by Swayampakula Ramakanth at HC Wainwright
7/19/2017HC WainwrightSet Price TargetBuy$7.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/22/2017HC WainwrightSet Price TargetBuy$7.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/7/2017HC WainwrightReiterated RatingBuy$7.00Low
i
8/30/2016HC WainwrightReiterated RatingBuyN/A
i
(Data available from 3/7/2016 forward)
Edap Tms logo
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. It operates in two divisions, High Intensity Focused Ultrasound (HIFU) and Urological Devices and Services (UDS). The HIFU division develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer. It also provides disposables, and leasing and treatment related services; and maintenance services. The UDS division develops, markets, manufactures, and services medical devices for the minimally invasive diagnosis or treatment of urological disorders primarily urinary stones and other clinical indications. This segment offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals; and Endo-UP platform, manages urinary stones, as well as Sonolith i-sys. It also leases lithotripters; sells disposables and spare parts; maintenance services; and distributes urodynamic products and urology lasers. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include public and private hospitals, urology clinics, and research institutions. The company was founded in 1979 and is headquartered in Lyon, France.
Read More

Today's Range

Now: $7.41
$6.86
$7.50

50 Day Range

MA: $8.63
$6.69
$10.60

52 Week Range

Now: $7.41
$1.46
$10.68

Volume

239,349 shs

Average Volume

296,248 shs

Market Capitalization

$215.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Edap Tms?

The following Wall Street sell-side analysts have issued reports on Edap Tms in the last twelve months: B. Riley, HC Wainwright, Lake Street Capital, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for EDAP.

What is the current price target for Edap Tms?

2 Wall Street analysts have set twelve-month price targets for Edap Tms in the last year. Their average twelve-month price target is $11.50, suggesting a possible upside of 55.2%. B. Riley has the highest price target set, predicting EDAP will reach $13.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $10.00 for Edap Tms in the next year.
View the latest price targets for EDAP.

What is the current consensus analyst rating for Edap Tms?

Edap Tms currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EDAP will outperform the market and that investors should add to their positions of Edap Tms.
View the latest ratings for EDAP.

What other companies compete with Edap Tms?

How do I contact Edap Tms' investor relations team?

Edap Tms' physical mailing address is Parc d'Activites la Poudrette-Lamartine 4/6 rue du Dauphine, Vaulx-en-Velin I0, 69120. The medical equipment provider's listed phone number is 33-04-72-15-31-50 and its investor relations email address is [email protected] The official website for Edap Tms is www.edap-tms.com.